Hi Kiwi, you have been calling out for real world data on V, for ever. Nothing seems to satisfy you, and that’s fair. You seem to be very knowledgeable about the mechanics of clinical trial. Imagine you are the CEO of Amarin with absolute authority to take any decisions on behalf of Amarin, including its cash reserve. Based on the current state of Amarin, including it’s balance sheet, what is the trial you would like to see Amarin fund for, whose results will truly convince you to stop asking for more real world data. At that point you call it either V is a hit or V is bust. No follow up trials. You just get one shot at it. Details like what kind of population you would like to include (age, country of residence, medical condition, etc) size of the trial, placebo to be used, trial duration, etc. More the technical details, better it is. This is my genuine question to you, if you mind to respond. Really curious.
News 
Market Data 
Discover 
